Global Leading Market Research Publisher QYResearch announces the release of its latest report “Plasma Volume Expander – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Plasma Volume Expander market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hospital executives, trauma center directors, pharmaceutical investors, and emergency medicine leaders, plasma volume expanders represent an indispensable category within acute care medical supplies. Hypovolemia (critically low blood volume) from trauma, surgical blood loss, burns, dehydration, or septic shock demands immediate intervention; failure to restore circulating volume leads to organ failure and death within minutes to hours. Plasma volume expanders are intravenous fluids designed specifically to increase blood plasma volume in patients suffering from blood loss, shock, or dehydration, helping maintain blood circulation and preventing hypovolemia by replenishing lost fluids. These expanders are classified into crystalloids (e.g., saline, Ringer’s lactate) and colloids (e.g., albumin, dextran, hydroxyethyl starch). For healthcare systems facing rising trauma caseloads, aging populations requiring complex surgeries, and expanding emergency care infrastructure globally, plasma volume expanders represent essential, non-discretionary consumables with stable, predictable demand.
The global market for Plasma Volume Expander was estimated to be worth USD 225 million in 2024 and is forecast to reach a readjusted size of USD 326 million by 2031, growing at a CAGR of 5.7% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4667792/plasma-volume-expander
1. Market Definition and Product Segmentation
Plasma volume expanders are intravenous fluids used to increase blood plasma volume in patients suffering from blood loss, shock, or dehydration. These expanders help maintain blood circulation and prevent hypovolemia (dangerously low circulating blood volume) by replenishing lost fluids.
Core Product Segments (QYResearch Data):
Human Albumin (approximately 35-40% of market value): The premium segment, derived from human plasma (pooled donor plasma, fractionated, purified, and viral-inactivated). Albumin solutions (5% or 25% concentration) provide natural oncotic pressure identical to human plasma, long intravascular retention (12-24 hours), and excellent safety profile. Primary applications: hypovolemic shock, burns, hypoalbuminemia (liver disease, nephrotic syndrome), and cardiopulmonary bypass surgery. Key players: CSL Behring, Kedrion Biopharma, Takeda Pharmaceuticals. Plasma supply constraints (collection capacity, donor availability) limit growth; manufacturers with integrated plasma collection networks maintain competitive advantage.
Colloids (Synthetic, approximately 25-30% of market value): Synthetic volume expanders including hydroxyethyl starch (HES), dextran, and gelatin-based solutions. Advantages over albumin: lower manufacturing cost (synthetic, no plasma dependency), longer shelf life, and no plasma supply constraints. Safety concerns (coagulopathy, anaphylaxis, renal toxicity) have led to regulatory restrictions in some markets (FDA boxed warning, EMA contraindications for HES in sepsis/critical illness). Key players: B. Braun, Fresenius Kabi, Pfizer.
Hydroxyethyl Starch (HES) (approximately 15-20% of market value, declining segment): A specific synthetic colloid with intermediate molecular weight and molar substitution. HES use has declined following safety warnings, though it remains approved for intraoperative volume replacement in surgical patients without sepsis or renal impairment in many markets. The segment is declining at 1-2% CAGR as hospitals shift to albumin (premium) or crystalloids (cost-effective) for hypovolemia management.
Plasma Protein Fraction (PPF) (approximately 5-10% of market value): A plasma-derived product containing albumin and other plasma proteins (alpha and beta globulins). Similar indications to albumin but less purified and lower cost. PPF has lost market share to recombinant and purified albumin products; segment growth is minimal.
Dextran (approximately 5-10% of market value, stable niche): A branched polysaccharide synthetic colloid with volume expansion and antithrombotic properties. Used for volume expansion and venous thromboembolism (VTE) prophylaxis in high-risk surgical patients. Higher anaphylaxis risk (0.1-1% of administrations) than other colloids limits broader adoption; segment maintains stable niche.
Application Segmentation:
Hospitals (approximately 60-70% of market value): The dominant segment, including emergency departments (trauma, hemorrhage, burns, sepsis), operating rooms (intraoperative blood loss management), intensive care units (critical illness, shock), and general wards. Hospitals require multiple product sizes (250ml, 500ml, 1000ml), compatibility with standard IV administration sets, and extended shelf life.
Clinics (approximately 15-20%): Ambulatory surgical centers, urgent care centers, and outpatient clinics performing procedures with fluid loss risk. Volume per facility is lower than hospitals, but serves as important secondary distribution channel.
Other (approximately 10-15%): Emergency medical services (EMS/ambulance pre-hospital resuscitation), military medical facilities (combat casualty care, forward surgical teams), and home infusion services.
2. Market Drivers and Growth Catalysts
As a senior industry analyst tracking this critical care segment, I have identified five primary growth drivers.
Driver 1 – Increasing Prevalence of Trauma and Surgery Cases: The rising number of accidents (road traffic injuries estimated at 20-50 million annually globally), surgical procedures (300-350 million annually, growing 3-5% pre-pandemic), and critical care treatments directly boosts demand for plasma expanders. Major surgeries (cardiovascular, orthopedic, abdominal, transplant) routinely require 500-2000ml of volume expanders for intraoperative fluid management. According to WHO data, trauma remains a leading cause of death and disability globally, with middle-income countries experiencing rapid motorization and associated injury rates.
Driver 2 – Rising Incidence of Hypovolemia and Shock Conditions: Increasing cases of hypovolemic shock due to burns (estimated 11 million burn injuries globally requiring medical attention), injuries (falls, workplace accidents, violence), and medical conditions (gastrointestinal bleeding, ruptured aneurysms, pancreatitis) drive market demand. Each severe burn (>20% total body surface area) requires aggressive fluid resuscitation (Parkland formula: 4ml x kg body weight x %TBSA), creating substantial volume expander requirements.
Driver 3 – Aging Population and Chronic Diseases: A growing elderly population prone to surgeries (cataract, joint replacement, cardiovascular) and chronic illnesses (diabetes, renal disease, liver disease, heart failure) fuels demand for plasma volume expanders. Patients with chronic diseases have higher surgical intervention rates and are more susceptible to conditions requiring volume resuscitation (sepsis, dehydration, bleeding complications). Global population aged 65+ is projected to reach 1.5 billion by 2050 (from 1 billion in 2020), creating sustained demand.
Driver 4 – Advancements in IV Fluid Technology: Continuous innovation in intravenous fluids and biocompatible formulations enhances product adoption. Ultra-low-VOC medical-grade materials, improved container systems (non-PVC, non-DEHP bags reducing extractable risks), and extended shelf-life formulations improve product appeal to hospital procurement. BASF’s development of low-VOC polymer emulsions exemplifies cross-industry innovation applicable to medical fluid packaging.
Driver 5 – Expansion of Healthcare Infrastructure: Improvements in hospitals, emergency care networks, trauma centers, and military medical facilities contribute to market growth. China’s Healthy China 2030 initiative, India’s Ayushman Bharat scheme, and various African and Southeast Asian healthcare infrastructure programs are expanding access to acute care. New facilities require equipping with emergency and surgical supplies, including volume expanders, creating initial stocking demand.
Exclusive Observation – Regional Growth Dynamics: Emerging economies (China, India, Southeast Asia, Latin America) are growing at 7-8% CAGR, significantly outpacing mature markets (North America 3-4%, Europe 2-3%). Chinese manufacturers (Huaren Pharmaceutical, Kelun Pharmacy, China Res Double-Crane) have gained domestic market share through lower pricing (20-30% below international brands) and regulatory relationships. India’s domestic manufacturers (Piramal Critical Care, Pentagon Labs) similarly serve price-sensitive segments. International players (B. Braun, Fresenius Kabi, CSL Behring) maintain premium positioning in tertiary care hospitals, academic medical centers, and private hospital chains.
3. Industry Development Characteristics and Competitive Landscape
As a senior industry analyst with three decades of experience, I observe several defining characteristics that differentiate the plasma volume expander market.
Characteristic 1 – Concentrated Market with Vertically Integrated Leaders: The plasma volume expander market is concentrated, with the top 5 players (B. Braun, Fresenius Kabi, CSL Behring, Takeda Pharmaceuticals, Pfizer) holding approximately 60-65% of global market share. Human albumin segment is highly concentrated among plasma fractionators (CSL Behring, Takeda, Kedrion, Grifols) due to high barriers: plasma collection infrastructure (USD 50-100 million investment for new fractionation facility), regulatory approvals (FDA, EMA, national health authorities, 5-8 years from facility construction to commercial sales), and donor center networks (500-1000 collection centers for large-scale operation). Synthetic colloid segment has lower barriers, with multiple regional manufacturers competing on price.
Characteristic 2 – Plasma Supply Constrains Albumin Growth: Human albumin (35-40% share) growth is directly limited by source plasma availability. Global plasma collection declined during COVID-19 (15-20% reduction) and has not fully recovered (estimated 5-10% below pre-pandemic levels by 2025). The US supplies approximately 70% of global source plasma due to compensated donation (paid donors, regulatory permitted) and established collection infrastructure. Manufacturers with integrated plasma collection (CSL Behring, Takeda, Kedrion) have supply advantage; manufacturers purchasing plasma on open market face price volatility and supply uncertainty. The market research indicates human albumin will maintain but not increase market share (35-40%) through 2031, constrained by plasma supply.
Characteristic 3 – HES Decline vs. Crystalloid Competition: Hydroxyethyl starch (15-20% share) continues declining (1-2% annual volume decrease) following FDA boxed warning (2013, HES not indicated for sepsis, burns, critical illness) and EMA contraindication (2018). Hospitals have shifted to albumin (preferred colloid for critical illness) or crystalloids (saline, Ringer’s lactate, balanced solutions) for most hypovolemia indications. HES persists in intraoperative use for surgical patients without sepsis or renal impairment where coagulopathy can be monitored. Crystalloid competition (not tracked in this market segment) provides lower-cost alternative (USD 1-5 per liter vs. USD 50-200 for albumin) for less severe hypovolemia, limiting colloid market expansion.
Characteristic 4 – Hospital Dominance with Long-Term Supplier Relationships: Hospitals (60-70% share) dominate, and procurement occurs through group purchasing organizations (GPOs, e.g., Vizient, Premier, Intalere in US), multi-year contracts (2-5 years), and national tenders (public healthcare systems in UK, Canada, Australia, European countries). Supplier switching requires regulatory notifications (change in medical device manufacturer requires hospital notification, some regulators require new product approval). These long-term relationships and switching costs benefit incumbent suppliers.
Exclusive Observation – Military and Disaster Preparedness as Demand Driver: Military medical facilities (combat casualty care, forward surgical teams) and disaster preparedness stockpiles (government strategic reserves for natural disasters, pandemic response, terrorist attacks) represent stable, non-cyclical demand. The US Department of Defense, NATO, and other national military medical services procure volume expanders as part of battlefield trauma kits and field hospital supplies. Disaster stockpiles (WHO, national emergency management agencies) require regular rotation (expiration dates), creating consistent replacement demand. This segment is less price-sensitive than civilian hospital procurement, offering favorable margins for suppliers.
4. Recent Regulatory and Market Developments (2024-2025)
According to pharmaceutical industry reports, the plasma volume expander market experienced post-pandemic normalization in 2024-2025 after supply chain disruptions (plasma collection declines, transportation delays, import/export restrictions). Manufacturers diversified supply chains (multiple raw material sources, regional production facilities) to mitigate future disruptions.
Regulatory updates: FDA continues monitoring HES safety through post-market surveillance. No major label changes issued in 2024-2025. EMA maintains existing HES contraindications (2018) without further restriction. China NMPA has not implemented Western HES restrictions, allowing broader HES use in Chinese hospitals, supporting regional market growth. European Pharmacopoeia updated albumin monograph (2024) with revised viral inactivation requirements, requiring recertification for plasma-derived albumin products.
User Case – Trauma Center Protocol Optimization: A US Level 1 trauma center updated its massive transfusion protocol in 2025 based on recent clinical evidence, prioritizing balanced resuscitation (crystalloids + albumin + blood products) for hemorrhagic shock patients, reserving HES only for intraoperative use in monitored surgical patients without sepsis or renal impairment. The center reported 8% improvement in 24-hour survival for severe trauma patients (Injury Severity Score >25) following protocol implementation. Albumin utilization increased 45% year-over-year, while HES utilization declined 60%.
User Case – Chinese Domestic Albumin Expansion: According to China National Medical Products Administration announcements in 2024-2025, Huaren Pharmaceutical and Kelun Pharmacy received approvals for new plasma fractionation facilities, increasing domestic human albumin production capacity by an estimated 30%. China previously relied on imported albumin (CSL Behring, Takeda, Kedrion, Grifols) for 60-70% of consumption. Domestic production enables lower hospital acquisition costs (20-30% below imported brands) and supply chain security (reduced foreign dependence). This development supports expansion of plasma volume expander usage in Chinese hospitals previously constrained by cost.
5. Strategic Outlook for Industry Executives and Investors
For CEOs and business unit leaders, several strategic considerations emerge.
First – Product Portfolio Strategy: Companies with both plasma-derived (albumin) and synthetic (HES, dextran) product lines should manage the HES decline (portfolio pruning, pricing discipline for remaining sales) while investing in albumin supply chain security (plasma collection expansion, fractionation capacity). Companies without plasma infrastructure should evaluate synthetic colloid innovation (next-generation biocompatible products with improved safety profiles) or partnership/licensing agreements with plasma fractionators.
Second – Geographic Expansion Priorities: Emerging markets (China, India, Southeast Asia, Latin America) offer 7-8% growth rates, double the global average. Entry strategies include: local manufacturing partnerships (avoiding import tariffs, reducing logistics costs), regulatory navigation (local clinical trial requirements, registration timelines, government tender participation), and pricing tiering (premium international brands for private hospitals, local brands for public hospitals).
Third – Value-Added Services: Beyond product supply, manufacturers can differentiate through: hospital protocol consulting (optimizing volume resuscitation protocols, reducing inappropriate HES use), inventory management systems (par level monitoring, expiration date tracking, automated replenishment), clinician education (CME-accredited programs on hypovolemia management, colloid vs. crystalloid evidence), and supply chain resilience (buffer inventory programs, emergency response stockpiles).
Fourth – Pipeline and Innovation Monitoring: Investors should monitor recombinant albumin development (eliminates plasma dependency, potentially lower cost, no pathogen risk) and next-generation synthetic colloids (reduced coagulopathy, anaphylaxis, renal toxicity). While commercial availability is unlikely before 2028-2030 for either category, breakthrough products could disrupt current market structure.
6. Conclusion – Defensive Growth in an Essential Acute Care Category
The Plasma Volume Expander market offers investors and industry participants a defensive growth profile (essential, non-discretionary consumables) with steady 5.7% CAGR from USD 225 million (2024) to USD 326 million (2031). Human albumin (35-40% share) dominates the premium segment but is plasma-supply constrained. Synthetic colloids (HES, dextran) face safety-related headwinds in Western markets but persist in regions with less restrictive regulation. Hospitals (60-70% share) are the dominant application channel. B. Braun, Fresenius Kabi, CSL Behring, Takeda Pharmaceuticals, and Pfizer lead the concentrated market. For executives, strategic priorities include albumin supply chain security, emerging market expansion, and synthetic colloid innovation. For investors, the market offers predictable, regulated growth with barriers to entry (plasma infrastructure, regulatory approvals, hospital relationships) protecting incumbents.
For detailed competitive benchmarking, regional adoption analysis, product type forecasts (human albumin, colloids, HES, PPF, dextran), application analysis (hospitals, clinics, other), and 36-month rolling projections across 8 major regions, the full QYResearch report provides actionable intelligence for strategic planning and investment decision-making.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
